Two areas that suffered relatively light damage, however, were pharmaceuticals and biotech. The main reason ... they were concentrating on levies being phased in, as opposed to the full 25% ...

Shares of the biotech Kymera Therapeutics are up 50% since Monday, when data from an early trial hinted that its pill might ...

Pharmaceutical and biotech stocks often are ... In injectable format, VK2735 is set to enter phase 3 development; the oral formulation is getting ready to enter phase 2. Viking's stock price ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Positioned to Unlock M&A Value through U.S. Manufacturing Amidst Geopolitical Complexities and Specialty Portfolio ...

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is ...